StockNews.com initiated coverage on shares of Oragenics (NYSEAMERICAN:OGEN – Get Rating) in a report published on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.
Oragenics Trading Down 0.7 %
NYSEAMERICAN OGEN opened at $3.01 on Tuesday. The stock’s 50-day moving average price is $3.56 and its two-hundred day moving average price is $2.25. The company has a market cap of $5.90 million, a PE ratio of -23.31 and a beta of 0.19. Oragenics has a 1 year low of $2.60 and a 1 year high of $24.00.
Institutional Trading of Oragenics
Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp increased its holdings in shares of Oragenics by 8.1% in the 1st quarter. State Street Corp now owns 495,563 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 37,338 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Oragenics by 24.4% in the 4th quarter. Renaissance Technologies LLC now owns 288,398 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 56,498 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Oragenics by 591.6% in the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 110,119 shares during the period. Institutional investors and hedge funds own 9.31% of the company’s stock.
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.